Cutaneous side effects of sorafenib and sunitinib;Effets secondaires cutanés du sorafenib et du sunitinib

Annales de Dermatologie et de Venereologie

Volumn 135, Issue 2, 2008, Pages 148-153

  Autier, J ^a   Mateus, C ^a   Wechsler, J ^a   Spatz, A ^a   Robert, C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB;

ARTICLE; CONTINUING EDUCATION; DRUG SAFETY; HUMAN; MULTIPLE CHOICE TEST; POSTGRADUATE EDUCATION; SELF EVALUATION; SKIN DISEASE;

ACRODERMATITIS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DRUG ERUPTIONS; HAIR DISEASES; HUMANS; INDOLES; NAIL DISEASES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; RAF KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SKIN;

EID: 43049127494     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2007.12.006     Document Type: Article

References (18)

1. Guillot B., and Bessis D. Aspects cliniques et prise en charge des effets secondaires cutanés des inhibiteurs du récepteur à l'EGF. Ann Dermatol Venereol 133 (2006) 1017-1020
2. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
3. Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 368 (2006) 1303-1304
4. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
5. Robert C., Soria J.C., Spatz A., Le Cesne A., Malka D., Pautier P., et al. Cutaneous side effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6 (2005) 491-500
6. Strumberg D., Richly H., Hilger R.A., Schleucher N., Korfee S., Tewes M., et al. Phase I clinical and pharmacocinetic study of the novel Raf kinase vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (2005) 965-972
7. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2005) 2505-2512
8. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitargeted tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
9. National Cancer Institute. Common terminology criteria for adverse events v 3.0. http://ctep.cancer.gov/reporting/ctc.html.
10. Young J.B., Will E.J., and Mulley G.P. Splinter haemorrhages: facts and fiction. J R Coll Physicians Lond 22 (1988) 240-243
11. Robert C., Faivre S., Raymond E., Armand J.P., and Escudier B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?. Ann Intern Med 143 (2005) 313-314
12. Kong H.H., Cowen E.W., Azad N.S., Dahut W., Gutierrez M., and Turner M.L. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 56 (2007) 171-172
13. Lacouture M.E., Desai A., Soltani K., Petronic-Rosic V., Laumann A.E., Ratain M.J., et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 31 (2006) 783-785
14. Robert C., Spatz A., Faivre S., Armand J.P., and Raymond E. Tyrosine kinase inhibition and grey hair. Lancet 361 (2003) 1056
15. Hensley M.L., and Ford J.M. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 40 (2003) 21-25
16. Valeyrie L., Bastuji-Garin S., Revuz J., Bachot N., Wechsler J., Berthaud P., et al. Adverse cutaneous reactions to imatinib (STI 571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 48 (2003) 201-206
17. Wu M., Hemesath T.J., Takemoto C.M., Horstmann M.A., Wells A.G., Price E.R., et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev 14 (2000) 301-312
18. Papin C., Barnier J.V., Eychene A., and Calothy G. Le gène B-raf code pour de multiples isoformes ayant une activité Mek-1 kinase. C R Seances Soc Biol Fil 189 (1995) 71-85